These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2903920)

  • 1. Psychosocial changes in persistently psychotic schizophrenic patients after an 80% reduction of neuroleptic medication [corrected].
    DeLuca A; Pittman D; Gutierrez JM; Faraone SV
    J Psychosoc Nurs Ment Health Serv; 1988 Aug; 26(8):13-7. PubMed ID: 2903920
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic dose reduction in persistently psychotic patients.
    Faraone SV; Green AI; Brown W; Yin P; Tsuang MT
    Hosp Community Psychiatry; 1989 Nov; 40(11):1193-5. PubMed ID: 2572532
    [No Abstract]   [Full Text] [Related]  

  • 3. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ideal and reality of neuroleptic relapse prevention.
    Kissling W
    Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363
    [No Abstract]   [Full Text] [Related]  

  • 5. [Neuroleptic large dose therapy of schizophrenias].
    Ungvári G; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Apr; 33(4):230-6. PubMed ID: 6114506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
    Leblanc G; Cormier H; Gagné MA; Vaillancourt S
    Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects.
    Tugg LA; Desai D; Prendergast P; Remington G; Reed K; Zipursky RB
    Schizophr Res; 1997 May; 25(1):71-8. PubMed ID: 9176929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of buspirone in seven schizophrenic subjects.
    Brody D; Adler LA; Kim T; Angrist B; Rotrosen J
    J Clin Psychopharmacol; 1990 Feb; 10(1):68-9. PubMed ID: 1968473
    [No Abstract]   [Full Text] [Related]  

  • 9. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients.
    Lindström EM; Ohlund LS; Lindström LH; Ohman A
    Psychiatry Res; 1992 May; 42(2):145-58. PubMed ID: 1352902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous versus targeted medication in schizophrenic outpatients: outcome results.
    Carpenter WT; Hanlon TE; Heinrichs DW; Summerfelt AT; Kirkpatrick B; Levine J; Buchanan RW
    Am J Psychiatry; 1990 Sep; 147(9):1138-48. PubMed ID: 1974743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
    Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
    Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment programme and long-term outcome in chronic schizophrenia.
    Kane JM
    Acta Psychiatr Scand Suppl; 1990; 358():151-7. PubMed ID: 1978476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of anticholinergic medication on memory in schizophrenia.
    Strauss ME; Reynolds KS; Jayaram G; Tune LE
    Schizophr Res; 1990; 3(2):127-9. PubMed ID: 1980611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia.
    Barnes TR; Liddle PF; Curson DA; Patel M
    Br J Psychiatry Suppl; 1989 Nov; (7):99-103. PubMed ID: 2575915
    [No Abstract]   [Full Text] [Related]  

  • 17. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
    Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J
    Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
    Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
    Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics.
    Spohn HE; Coyne L; Lacoursiere R; Mazur D; Hayes K
    Arch Gen Psychiatry; 1985 Sep; 42(9):849-59. PubMed ID: 2864028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients.
    Smith RC
    Arch Gen Psychiatry; 1994 May; 51(5):427-9. PubMed ID: 7910013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.